How to track your ApoB over time

Apolipoprotein B, or ApoB, used to be a specialist’s test. It now turns up on more routine lipid orders, in direct-to-consumer panels, and in the 2026 U.S. cholesterol guideline. Most people who have an ApoB result have only one or two, drawn years apart, often at a different lab from their usual lipid panel. Read alone, each one is a number against a printed cutoff. Read next to your LDL and non-HDL cholesterol from the same draws, ApoB can show something the standard panel misses: whether you carry more particles than your cholesterol numbers suggest.

What ApoB measures

Every particle that can build plaque in the arteries, whether LDL, the remnants of triglyceride-rich VLDL, IDL, or Lp(a), carries exactly one ApoB molecule. Counting ApoB therefore counts those particles. The National Lipid Association’s 2024 consensus on ApoB describes it as “the total concentration of atherogenic lipoprotein particles in the circulation.”

LDL cholesterol measures something different: the amount of cholesterol carried inside LDL particles. Non-HDL cholesterol measures the cholesterol inside all of the ApoB-carrying particles. Usually the three move together. When particles are small and carry less cholesterol each, which is common with high triglycerides, diabetes, and obesity, the cholesterol numbers can look reassuring while the particle count is high.

When ApoB and LDL disagree

Across a population, ApoB and LDL cholesterol are closely related. In one person they can point in different directions. This is called discordance. In the Copenhagen General Population Study, which followed 13,015 people taking statins for a median of 8 years, ApoB above the median with LDL below it was linked to a higher risk of heart attack (hazard ratio 1.49) compared with both below the median. High LDL with low ApoB carried no extra risk. The NLA consensus reaches the same conclusion more broadly: when LDL and ApoB disagree, risk generally follows ApoB or non-HDL cholesterol.

Treatment widens the gap. A pooled analysis of 11 trials covering 17,035 people found that statins, alone or with ezetimibe, lowered LDL cholesterol by an average of 42 percent but ApoB by only 33 percent. On treatment, an LDL that looks low by population standards often corresponds to an ApoB that is only middling. That is one reason ApoB is ordered for people already on a statin.

The numbers on the report

ApoB is reported in mg/dL in the United States and often in g/L elsewhere. These are the same measurement on different scales: 1 g/L is 100 mg/dL, so an ApoB of 0.90 g/L is 90 mg/dL. Unlike cholesterol, there is no molar conversion to worry about. Convert everything to one unit before you chart it, or a switch of lab will look like a hundredfold drop.

The cutoffs come from guidelines, and they do not all agree:

The 2018 guideline has since been replaced, but its 130 mg/dL line is still printed on some reports. The NLA notes that an ApoB of 130 sits at about the 90th percentile of untreated U.S. adults, roughly where an LDL of 160 sits. In the same national data, the median untreated adult had an ApoB of 90 mg/dL and an LDL of 112.

The 2026 ACC/AHA dyslipidemia guideline uses ApoB selectively. It says measuring ApoB “may be used to assess any residual ASCVD risk and guide treatment” in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, or high triglycerides who have already reached their LDL and non-HDL goals. A review of the guideline adds that it points in particular to people whose achieved LDL is below 70 mg/dL. The guideline does not recommend ApoB for everyone. In Europe, the same review notes, the 2025 focused update kept LDL as the main target, with ApoB and non-HDL as secondary targets.

Your lab’s printed range is a separate thing again, and labs differ. Why are lab reference ranges different between labs? explains why. Your clinician sets your goal from your overall risk, not from the column on the report.

How often it is tested

ApoB is not on the standard lipid panel, so it is tested only when someone orders it. The NLA consensus lists two main occasions:

• An initial evaluation, to look for discordance with LDL and non-HDL or to spot a very high level.
• 4 to 12 weeks after a change in treatment, whether starting, increasing, or reducing a cholesterol medication, to see whether ApoB came down along with LDL.

After that, many people have ApoB checked alongside their lipid panel on stable treatment, at whatever interval their clinician sets for the panel. If your history has ApoB at only some draws, that is normal. Keep each result with the lipid panel drawn the same day, because ApoB means the most next to the LDL and non-HDL from that draw.

What counts as a real change

ApoB is one of the steadier lipid measurements, both in the body and in the lab.

• Biological variation. The EFLM Biological Variation Database, which pools nine studies, puts the within-person variation of ApoB at about 6 percent from one draw to the next.
• Lab accuracy. ApoB assays are standardized. The NLA consensus cites a College of American Pathologists survey in which the bias of most ApoB tests was below 4 mg/dL. The 2019 ESC/EAS guideline notes that standardized, automated, and inexpensive ApoB assays are available, and that ApoB performs better analytically than LDL or non-HDL, whether measured or calculated.

A common rule of thumb for comparing two results multiplies the within-person variation by about 2.8. For ApoB that means a change of up to about 17 percent can happen with nothing changed, before adding any error from the lab. On an ApoB of 90 mg/dL, that is roughly 15 mg/dL in either direction. A drop from 90 to 85 is not news. A drop from 120 to 75 after starting a statin is.

As with any test, a single result that breaks from your pattern is worth repeating before anyone acts on it. Several results moving the same way say more than one.

Things that move ApoB

• Fasting. It barely matters. The NLA consensus explains that routine assays measure both the ApoB on LDL-type particles and the ApoB on particles from a recent meal, but that there is “minimal change in apoB levels in the fasting compared to the non-fasting state.” The 2019 ESC/EAS guideline makes the same point. This makes ApoB easier to compare across draws than triglycerides or calculated LDL.
• Statins. They lower ApoB, though by a smaller percentage than LDL, as above.
• Ezetimibe. In the IMPROVE-IT trial, as summarized by the NLA, adding ezetimibe to simvastatin lowered ApoB by an additional 15 percent.
• PCSK9 inhibitors. Evolocumab or alirocumab added to a statin lowered ApoB by more than 40 percent in the outcome trials the NLA reviewed. In FOURIER, the median ApoB on evolocumab at 48 weeks was 38 mg/dL.
• Diet, weight, and triglycerides. Changes that lower triglycerides do not always lower ApoB. The 2026 guideline review notes a trial in which ApoB rose slightly even as other lipid numbers improved. A drop in triglycerides alone does not mean fewer particles.
• Everything that moves a lipid panel. A recent illness, pregnancy, a thyroid change, or a new medication can shift your lipids. How to track your cholesterol over time lists them. Note any of these next to an ApoB result too.

Did the medication actually do anything? covers reading a before-and-after fairly. For ApoB, the key is a good “before”: an ApoB drawn before treatment started, or before the last dose change.

Tracking ApoB alongside LDL and non-HDL

ApoB is most useful read against the cholesterol numbers from the same draw. A few ways to do that:

• Compare each to its own threshold. If your clinician uses the NLA’s matching thresholds, an LDL below 70 should come with an ApoB below 70. An LDL at goal with ApoB well above it is discordance.
• Compare percent changes after a medication change. Expect ApoB to fall by a smaller percentage than LDL on a statin. If it falls by much less, that is worth raising.
• Look at non-HDL too. Non-HDL cholesterol counts the cholesterol in the same particles ApoB counts, and it comes free with every lipid panel. The non-HDL cholesterol calculator works it out from your total and HDL, and the LDL cholesterol calculator shows how far the LDL equations differ for your numbers. When ApoB is missing from a draw, non-HDL is the next best line.

The ApoB/ApoA1 ratio

Some labs also measure apolipoprotein A1, the main protein on HDL particles, and report the ApoB/ApoA1 ratio. In the INTERHEART study of heart attacks in 52 countries, people in the top fifth of the ratio had about three times the odds of a heart attack of people in the bottom fifth. It is not among the treatment targets in the guidelines above. If your reports include it, chart it as its own line. It is a ratio, so it has no unit and does not change between mg/dL and g/L. The ApoB/ApoA1 ratio calculator works it out from your two results.

Lp(a) is inside ApoB

Each Lp(a) particle also carries one ApoB, so Lp(a) particles are counted in your ApoB. Lp(a) behaves very differently over time, though, and is usually measured once. How to track your Lp(a) over time covers it.

What to record with each result

For each ApoB result, keep:

ApoB goes by several names on reports: ApoB, Apo B, Apolipoprotein B, Apolipoprotein B-100, and ApoB-100. Pick one name and use it everywhere, or your history will split into short, separate lines.

Charting it

A few choices make an ApoB chart honest:

• Draw your goal on it, not just the lab’s cutoff. If your target is 70, a chart shaded to 130 hides the distance.
• Put ApoB and LDL on one chart. They share a scale in mg/dL and move together most of the time, so a gap that opens between them is easy to see.
• Space points by date. ApoB is often measured years apart. Five years and five weeks should not look the same.
• Mark medication starts and dose changes, and look at the first result 4 to 12 weeks after each.
• Convert g/L to mg/dL before plotting. Mixed units on one chart are meaningless.

How to track your lab results over time has the general method for any test.

Tracking ApoB in HealthViewer

HealthViewer is a lab results tracker that runs on your own computer. It imports ApoB from lab report PDFs, MyChart downloads, and direct connections to your health system. Results your health system sends with the standard code for ApoB are filed as Apolipoprotein B, and so are reports that print the name in capitals. Results in g/L are converted so they share one chart with results in mg/dL. If one of your labs prints a different name, such as Apo B, you can combine them with Merge in the Test Catalog.

In Trends, the overlay view puts ApoB and LDL on one chart. ApoB is not in the built-in Heart tag, so add the tag to it in the Test Catalog if you want it to come up with the rest of your lipids. Set your ApoB goal as a custom range there too, and the chart shades your target instead of the lab’s cutoff. Medication markers show where a statin or a PCSK9 inhibitor started. Enter each dose as its own period in Medications, and every dose change gets a marker. The journal holds the rest, such as an illness or a change of lab.

If your lab reports ApoA1 but not the ratio, you can create the ApoB/ApoA1 ratio as a derived test in Settings: a formula of A ÷ B with ApoB and ApoA1 as the variables and no unit.

Everything stays in an encrypted file on your computer, with no account and no cloud service. Getting Started walks through the first import.

This post is general information, not medical advice. Talk to your clinician about your ApoB goal and before changing any treatment.